In fact, in the context of the IGF system, this affects both the quantification of cancer-specific IGF-II (o-glycosylated IGF-II pro-hormone) as well as the insulin receptor fetal isoform variant (IRA) in patient-derived cancer cells. The gene discussed is INSR; the disease is cancer.